Literature DB >> 22089192

Reduced peroxisome proliferator-activated receptor α expression is associated with decreased survival and increased tissue bacterial load in sepsis.

Stephen W Standage1, Charles C Caldwell, Basilia Zingarelli, Hector R Wong.   

Abstract

The peroxisome proliferator-activated receptor α (PPAR-α) is a member of the nuclear receptor family with many important physiologic roles related to metabolism and inflammation. Previous research in pediatric patients with septic shock revealed that genes corresponding to the PPAR-α signaling pathway are significantly downregulated in a subgroup of children with more severe disease. In this study, PPAR-α expression analysis using whole-blood derived RNA revealed that PPAR-α expression was decreased in patients with septic shock and that the magnitude of that decrement correlated with the severity of disease. In a mouse model of sepsis, induced by cecal ligation and puncture, knockout mice lacking PPAR-α had decreased survival compared with wild-type animals. Plasma cytokine analysis demonstrated decreased levels of interleukin 1β (IL-1β), IL-6, IL-17, keratinocyte-derived cytokine, macrophage chemoattractant protein 1, macrophage inflammatory protein 2, and tumor necrosis factor α at 24 h in PPAR-α knockout animals. Cell surface markers of activation on splenic dendritic cells, macrophages, and CD8 T cells were reduced in PPAR-α null animals, and the bacterial load in lung and splenic tissues was increased. These data indicate that reduced or absent PPAR-α expression confers a survival disadvantage in sepsis and that PPAR-α plays a role in maintaining appropriate immune functions during the sepsis response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22089192      PMCID: PMC3261332          DOI: 10.1097/SHK.0b013e31823f1a00

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  36 in total

Review 1.  Roles of PPARs in health and disease.

Authors:  S Kersten; B Desvergne; W Wahli
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

2.  'PPAR'ting ways with inflammation.

Authors:  Shannon T Bailey; Sankar Ghosh
Journal:  Nat Immunol       Date:  2005-10       Impact factor: 25.606

Review 3.  An overview on biological mechanisms of PPARs.

Authors:  Bhavani Prasad Kota; Tom Hsun-Wei Huang; Basil D Roufogalis
Journal:  Pharmacol Res       Date:  2005-02       Impact factor: 7.658

Review 4.  Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.

Authors:  Daniel S Straus; Christopher K Glass
Journal:  Trends Immunol       Date:  2007-11-05       Impact factor: 16.687

5.  Peroxisome proliferator-activated receptor-alpha modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice.

Authors:  Luisa Riccardi; Emanuela Mazzon; Stefano Bruscoli; Emanuela Esposito; Concetta Crisafulli; Rosanna Di Paola; Rocco Caminiti; Carlo Riccardi; Salvatore Cuzzocrea
Journal:  Shock       Date:  2009-03       Impact factor: 3.454

6.  The sepsis seesaw: tilting toward immunosuppression.

Authors:  Richard S Hotchkiss; Craig M Coopersmith; Jonathan E McDunn; Thomas A Ferguson
Journal:  Nat Med       Date:  2009-05       Impact factor: 53.440

Review 7.  The PPAR trio: regulators of myocardial energy metabolism in health and disease.

Authors:  Jose A Madrazo; Daniel P Kelly
Journal:  J Mol Cell Cardiol       Date:  2008-04-04       Impact factor: 5.000

Review 8.  The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity.

Authors:  Pascal Ferré
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

9.  Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury.

Authors:  M B Schaefer; A Pose; J Ott; M Hecker; A Behnk; R Schulz; N Weissmann; A Günther; W Seeger; K Mayer
Journal:  Eur Respir J       Date:  2008-07-24       Impact factor: 16.671

10.  Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock.

Authors:  Thomas P Shanley; Natalie Cvijanovich; Richard Lin; Geoffrey L Allen; Neal J Thomas; Allan Doctor; Meena Kalyanaraman; Nancy M Tofil; Scott Penfil; Marie Monaco; Kelli Odoms; Michael Barnes; Bhuvaneswari Sakthivel; Bruce J Aronow; Hector R Wong
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

View more
  40 in total

1.  Nonhematopoietic Peroxisome Proliferator-Activated Receptor-α Protects Against Cardiac Injury and Enhances Survival in Experimental Polymicrobial Sepsis.

Authors:  Stephen W Standage; Rachel L Waworuntu; Martha A Delaney; Sara M Maskal; Brock G Bennion; Jeremy S Duffield; William C Parks; W Conrad Liles; John K McGuire
Journal:  Crit Care Med       Date:  2016-08       Impact factor: 7.598

Review 2.  Early Diagnosis of Sepsis: Is an Integrated Omics Approach the Way Forward?

Authors:  Raymond J Langley; Hector R Wong
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

3.  PPARα augments heart function and cardiac fatty acid oxidation in early experimental polymicrobial sepsis.

Authors:  Stephen W Standage; Brock G Bennion; Taft O Knowles; Dolena R Ledee; Michael A Portman; John K McGuire; W Conrad Liles; Aaron K Olson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-11-23       Impact factor: 4.733

4.  An integrated clinico-metabolomic model improves prediction of death in sepsis.

Authors:  Raymond J Langley; Ephraim L Tsalik; Jennifer C van Velkinburgh; Seth W Glickman; Brandon J Rice; Chunping Wang; Bo Chen; Lawrence Carin; Arturo Suarez; Robert P Mohney; Debra H Freeman; Mu Wang; Jinsam You; Jacob Wulff; J Will Thompson; M Arthur Moseley; Stephanie Reisinger; Brian T Edmonds; Brian Grinnell; David R Nelson; Darrell L Dinwiddie; Neil A Miller; Carol J Saunders; Sarah S Soden; Angela J Rogers; Lee Gazourian; Laura E Fredenburgh; Anthony F Massaro; Rebecca M Baron; Augustine M K Choi; G Ralph Corey; Geoffrey S Ginsburg; Charles B Cairns; Ronny M Otero; Vance G Fowler; Emanuel P Rivers; Christopher W Woods; Stephen F Kingsmore
Journal:  Sci Transl Med       Date:  2013-07-24       Impact factor: 17.956

5.  Peroxisome proliferator-activated receptor alpha mediates C/EBP homologous protein to protect mice from acute liver failure.

Authors:  Xiangying Zhang; Peiling Dong; Hongbo Shi; Huaying Sun; Jianhui Lin; Dexi Chen; Zhongping Duan; Xiuhui Li; Feng Ren
Journal:  Inflamm Res       Date:  2017-06-09       Impact factor: 4.575

6.  Second Generation Triple-Helical Peptide Inhibitors of Matrix Metalloproteinases.

Authors:  Manishabrata Bhowmick; Dorota Tokmina-Roszyk; Lillian Onwuha-Ekpete; Kelli Harmon; Trista Robichaud; Rita Fuerst; Roma Stawikowska; Bjorn Steffensen; William Roush; Hector R Wong; Gregg B Fields
Journal:  J Med Chem       Date:  2017-04-19       Impact factor: 7.446

Review 7.  The inflammatory response in sepsis.

Authors:  Markus Bosmann; Peter A Ward
Journal:  Trends Immunol       Date:  2012-10-02       Impact factor: 16.687

8.  A PPARγ AGONIST ENHANCES BACTERIAL CLEARANCE THROUGH NEUTROPHIL EXTRACELLULAR TRAP FORMATION AND IMPROVES SURVIVAL IN SEPSIS.

Authors:  Cláudia V Araújo; Clarissa Campbell; Cassiano F Gonçalves-de-Albuquerque; Raphael Molinaro; Mark J Cody; Christian C Yost; Patricia T Bozza; Guy A Zimmerman; Andrew S Weyrich; Hugo C Castro-Faria-Neto; Adriana R Silva
Journal:  Shock       Date:  2016-04       Impact factor: 3.454

9.  Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α.

Authors:  Deborah D Crane; Robin Ireland; Joshua B Alinger; Pamela Small; Catharine M Bosio
Journal:  Clin Vaccine Immunol       Date:  2013-08-07

10.  2-Chlorofatty acids are biomarkers of sepsis mortality and mediators of barrier dysfunction in rats.

Authors:  Daniel P Pike; Michael J Vogel; Jane McHowat; Paul A Mikuzis; Kevin A Schulte; David A Ford
Journal:  J Lipid Res       Date:  2020-05-06       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.